Long-Term Benefit of Sotorasib in Patients With KRAS G12C–Mutated Non–Small-Cell Lung Cancer: Plain Language Summary
この論文をさがす
説明
This is a plain language summary of a study called CodeBreaK 100. The CodeBreaK 100 study included patients with non-small-cell lung cancer that had spread outside the lung (advanced). Lung cancer is one of the most common forms of cancer. CodeBreaK 100 specifically looked at patients with a particular change(mutation) in theIn total, 174 adults were treated with sotorasib.Results show the long-term benefit of sotorasib therapy for people with advanced
収録刊行物
-
- Future Oncology
-
Future Oncology 20 113-120, 2023-11-27
Informa UK Limited
